GEA
FOLD

Glen Eagle Advisors’s Amicus Therapeutics FOLD Stock Holding History

Glen Eagle Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250
Closed -$3.53K – 993
2020
Q3 		$3.53K Hold
250
– – ﹤0.01% 735
2020
Q2 		$3.77K Buy
250
+100
+67% +$1.22K ﹤0.01% 700
2020
Q1 		$1.39K Hold
150
– – ﹤0.01% 732
2019
Q4 		$1.46K Sell
150
-150
-50% -$1.37K ﹤0.01% 805
2019
Q3 		$2.41K Hold
300
– – ﹤0.01% 698
2019
Q2 		$3.74K Buy
+300
New +$3.81K ﹤0.01% 650

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glen Eagle Advisors's FOLD Position: Q4 2020 in Review

Glen Eagle Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2020, closing a stake of 250 shares — an estimated $3.53K sold.

Glen Eagle Advisors first reported a position in FOLD in Q2 2019 and held it in 6 quarters. The position peaked at $3.77K in Q2 2020. 271 funds tracked by Wall St. Rank hold FOLD as of Q4 2020.

  • Glen Eagle Advisors reported no remaining Amicus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glen Eagle Advisors sold 250 Amicus Therapeutics shares in Q4 2020, an estimated $3.53K.
  • Glen Eagle Advisors first reported a position in Amicus Therapeutics in Q2 2019 and held it in 6 quarters.
  • Glen Eagle Advisors's Amicus Therapeutics position peaked at $3.77K in Q2 2020.
  • 271 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2020.

Based on Glen Eagle Advisors's 13F filing for Q4 2020, filed 13 Aug 2024.